Treating Myelodysplastic Syndromes Transformation to Acute Myeloid Leukemia(Nurse)

Credit Available: AANP, CABRN, CME

 

Enroll in this Course

FREE

access until October 20, 2025 12:00 am

 

Enroll Now

Activity Description

This recorded webinar provides in-depth information about the clinical complexities and management strategies associated with the transition of Myelodysplastic Syndromes (MDS) to Acute Myeloid Leukemia (AML). The program will offer a comprehensive overview of the pathophysiology, diagnostic criteria, and treatment options, including new and emerging therapies. This program aims to equip participants with the knowledge and resources needed to make informed decisions when treating these patients and providing patient and family education and support.

Time to Complete Activity: 1.0 hours

This course is available from:

October 10, 2024 until October 20, 2025

Course Instructors

Aref Al-Kali Al-Kali, MD Speaker

Professor of Medicine, MDS Clinic Director, Acute Myeloid Group Chair, Section Head, Division of Hematology, Mayo Clinic,  Rochester, MN 

Jennifer Andres, MSN, RN, FNP-C Speaker

Outpatient Hematology Nurse Practitioner, Mayo Clinic, Phoenix, AZ

Target Audience

This activity is intended for hematologist/oncologists, oncology nurses, nurse practitioners, and other healthcare professionals involved in the care of patients with hematologic malignancies.

Educational Objectives
After completing this activity, the participant should be better able to:

• Provide an overview of Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

• Explain the progression from MDS to AML, including the factors that influence the transformation and the clinical implications

• Discuss the diagnostic criteria for distinguishing MDS from AML

• Describe the treatment options and management strategies for both MDS and AML, including emerging therapies

• Review resources and education to support patients, caregivers, and healthcare professionals

•  

Accreditation, Support and Credit

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute Inc and The Leukemia & Lymphoma Society. Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Medical Learning Institute Inc (MLI) designates this enduringfor a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Registered Nursing Credit Designation

Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.0 continuing education contact hour through the California Board of Registered Nursing.

Nurse Practitioner Continuing Education

This education activity will be submitted to the American Association of Nurse Practitioners® for approval of up to XX contact hours of accredited.

Supporters

There is no commercial support associated with this CE activity.

Providers

 

This activity is provided by The Leukemia & Lymphoma Society and Medical Learning Institute Inc

Disclosure of Conflicts of Interest Policy

Medical Learning Institute Inc, and The Leukemia & Lymphoma Society are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.

To that end, MLI & LLS require faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI & LLS policy. These disclosures will be provided to learners prior to the start of the CE activity.

Faculty Disclosures

Aref Al-Kali, MD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor (support to institution): Novartis
Research Funding (support to institution): ALX Oncology, Aprea, Astex, H3B/Hemavant, Novartis

Jennifer Andres, MSN, RN, FNP-C, has no relevant financial relationships with ineligible companies to disclose for this educational activity.

*All of the relevant financial relationships of individuals for this activity have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute Inc and The Leukemia & Lymphoma Society do not have any relevant financial relationships to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the accredited CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the activity posttest, evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute Inc

For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

If you have questions regarding your certificate, please contact Mary Vu via email at mvu@mlieducation.org

About this Activity

Medical Learning Institute Inc and The Leukemia & Lymphoma Society are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute Inc or any of its partners, providers, and/or supporters.

Copyright © 2024 Medical Learning Institute Inc All Rights Reserved.